👤 Lorenz IP

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
6
Articles
5
Name variants
Also published as: Ejidike IP, López IP, Filipović IP, WKE Ip
articles
Millán G, Nieddu M, López IP +5 more · 2023 · Dalton Transactions · Royal Society of Chemistry · added 2026-05-01
Title: A new family of luminescent iridium complexes: synthesis, optical, and cytotoxic studies. Abstract: By using N,N-dibutyl-2,2'-bipyridine-4,4'-dicarboxamide as a diimine (dbbpy) and distinctive Show more
Title: A new family of luminescent iridium complexes: synthesis, optical, and cytotoxic studies. Abstract: By using N,N-dibutyl-2,2'-bipyridine-4,4'-dicarboxamide as a diimine (dbbpy) and distinctive cyclometalated groups, this work reports a new family of cationic phosphorescent Ir(III) cyclometalated [Ir(C^N)2(N^N)]X compounds [C^N = difluorophenylpyridine (dfppy) a, 2,6-difluoro-3-(pyridin-2-yl)benzaldehyde (CHO-dfppy) b, and 2,6-difluoro-3-pyridin-2-yl-benzoic acid (COOH-dfppy) c; X = Cl-2a,b,c-Cl; X = PF6-2b,c-PF6]. For comparative purposes, the related complex [Ir(dfppy)2(H2dcbpy)]+ (3a-PF6) incorporating 3,3'-dicarboxy-2,2'-bipyridine as an auxiliary ligand (N^N = H2dcbpy) is also presented. All complexes have been fully characterized and their photophysical properties were investigated in detail. The theoretically calculated results obtained by density functional theory (DFT) and time-dependent density functional theory (TD-DFT) studies indicate that luminescence is derived from mixed 3ML'CT (Ir → N^N)/3LL'CT (C^N → N^N) excited states with the predominant metal-to-diimine charge transfer character. Their antineoplastic activity against tumour cell lines A549 (lung carcinoma) and HeLa (cervix carcinoma), as well as the nontumor BEAS-2B (bronchial epithelium) cell line was assessed and fluorescence microscopy studies were performed for their cellular localization. Among them, 2a-Cl exhibited the most potent anticancer activity, being higher than cisplatin. However, 2b-Cl and 2c-Cl,-PF6 were the least toxic, while 2b-PF6 and 3a-PF6 exhibited only moderate activity. Confocal microscopy studies for 2a-Cl suggest that complexes localize preferentially in the lysosomes and to a lesser extent in the cytoplasm, but ultimately causing damage to the mitochondria. Finally, the potential photodynamic behaviour of scarcely toxic complexes 2b-Cl, 2b-PF6, 2c-Cl and 3a-PF6 was also studied. Show less
no PDF DOI: 10.1039/d3dt00028a
Biometal
Đukić MB, Jeremić MS, Filipović IP +6 more · 2020 · Journal of Inorganic Biochemistry · Elsevier · added 2026-05-01
Three new ruthenium(II) complexes were synthesized from different substituted isothiazole ligands 5-(methylamino)-3-pyrrolidine-1-ylisothiazole-4-carbonitrile (1), 5-(methylamino)-3-(4-methylpiperazin Show more
Three new ruthenium(II) complexes were synthesized from different substituted isothiazole ligands 5-(methylamino)-3-pyrrolidine-1-ylisothiazole-4-carbonitrile (1), 5-(methylamino)-3-(4-methylpiperazine-1-yl)isothiazole-4-carbonitrile (2) and 5-(methylamino)-3-morpholine-4-ylisothiazole-4-carbonitrile (3): [Ru(η6-p-cymene)Cl2(L1)]·H2O (4), [Ru(η6-p-cymene)Cl2(L2)] (5) and [Ru(η6-p-cymene)Cl2(L3)] (6). All complexes were characterized by IR, UV-Vis, NMR spectroscopy, and elemental analysis. The molecular structures of all ligands and complexes 4 and 6 were determined by an X-ray. The results of the interactions of CT-DNA (calf thymus deoxyribonucleic acid) and HSA (human serum albumin) with ruthenium (II) complexes reveal that complex 4 binds well to CT-DNA and HSA. Kinetic and thermodynamic parameters for the reaction between complex and HSA confirmed the associative mode of interaction. The results of Quantum mechanics (QM) modelling and docking experiments toward DNA dodecamer and HSA support the strongest binding of the complex 4 to DNA major groove, as well as its binding to IIa domain of HSA with the lowest ΔG energy, which agrees with the solution studies. The modified GOLD docking results are indicative for Ru(p-cymene)LCl··(HSA··GLU292) binding and GOLD/MOPAC(QM) docking/modelling of DNA/Ligand (Ru(II)-N(7)dG7) covalent binding. The cytotoxic activity of compounds was evaluated by MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay. Neither of the tested compounds shows activity against a healthy MRC-5 cell line while the MCF-7 cell line is the most sensitive to all. Compounds 3, 4 and 5 were about two times more active than cisplatin, while the antiproliferative activity of 6 was almost the same as with cisplatin. Flow cytometry analysis showed the apoptotic death of the cells with a cell cycle arrest in the subG1 phase. Show less
📄 PDF DOI: 10.1016/j.jinorgbio.2020.111256
Biometal
V Hotamisligil, ED Werner, J Giraud +1206 more · 2017 · Immunity · Elsevier · added 2026-04-20
V Hotamisligil, ED Werner, J Giraud, YH Lee, SE Shoelson, MF White, MC Arkan, AL Hevener, FR Greten, S Maeda, ZW Li, JM Long, A Wynshaw-Boris, G Poli, J Olefsky, M Karin, N Arpaia, C Campbell, X Fan, S Dikiy, J van der Veeken, P deRoos, H Liu, JR Cross, K Pfeffer, PJ Coffer, DB Ballak, R Stienstra, A Hijmans, LA Joosten, MG Netea, CJ Tack, PJ Barnes, AM Bernstein, MF Roizen, L Martinez, SA Berson, RS Yalow, B Beutler, D Greenwald, JD Hulmes, M Chang, YC Pan, J Mathison, R Ulevitch, A Cerami, P Bhargava, C Li, KJ Stanya, D Jacobi, L Dai, S Liu, MR Gangl, DA Harn, CH Lee, G Boden, X Duan, C Homko, EJ Molina, W Song, O Perez, P Cheung, S Merali, E Boriushkin, JJ Wang, J Li, M Bhatta, SX Zhang, SE Borst, GJ Bagby, JR Brestoff, BS Kim, SA Saenz, RR Stine, LA Monticelli, GF Sonnenberg, JJ Thome, DL Farber, K Lutfy, P Seale, JS Burrill, EK Long, B Reilly, Y Deng, IM Armitage, PE Scherer, DA Bernlohr, V Byles, AJ Covarrubias, I Ben-Sahra, DW Lamming, DM Sabatini, BD Manning, T Horng, D Cai, M Yuan, DF Frantz, PA Melendez, L Hansen, J Lee, JS Campbell, L Prichard, F Schaper, J Schmitz, A Stephenson-Famy, ME Rosenfeld, GM Argast, PC Heinrich, N Fausto, H Cao, K Gerhold, JR Mayers, MM Wiest, SM Watkins, GS Hotamisligil, M Sekiya, ME Ertunc, MF Burak, A White, K Inouye, LM Rickey, BC Ercal, M Furuhashi, SS Cao, KL Luo, L Shi, EA Carswell, LJ Old, RL Kassel, S Green, N Fiore, B Williamson, CH Chang, JD Curtis, LB Maggi, B Faubert, AV Villarino, D O'Sullivan, SC Huang, GJ van der Windt, J Blagih, J Qiu, HR Chang, HJ Kim, X Xu, AW Ferrante, YH Chang, KT Ho, SH Lu, CN Huang, MY Shiau, A Chawla, KD Nguyen, YP Goh, KW Cho, BF Zamarron, LA Muir, K Singer, CE Porsche, JB DelProposto, L Geletka, KA Meyer, RW O'Rourke, CN Lumeng, KJ Chung, A Chatzigeorgiou, M Economopoulou, R Garcia-Martin, VI Alexaki, I Mitroulis, M Nati, J Gebler, T Ziemssen, SE Goelz, I Cimen, B Kocaturk, S Koyuncu, O Tufanli, UI Onat, AD Yildirim, O Apaydin, S Demirsoy, ZG Aykut, UT Nguyen, DE Cintra, JR Pauli, EP Araujo, JC Moraes, CT de Souza, M Milanski, J Morari, A Gambero, MJ Saad, LA Velloso, P Cohen, JD Levy, Y Zhang, A Frontini, DP Kolodin, KJ Svensson, JC Lo, X Zeng, L Ye, MJ Khandekar, KD Copps, P Cornelius, M Marlowe, MD Lee, PH Pekala, RM da Costa, KB Neves, FL Mestriner, P Louzada-Junior, T Bruder-Nascimento, RC Tostes, P Darkhal, M Gao, Y Ma, D Liu, JE Davis, NK Gabler, J Walker-Daniels, ME Spurlock, S Bordin, R Ashimine, RL Zollner, AC Boschero, J DeFuria, AC Belkina, M Jagannathan-Bogdan, J Snyder-Cappione, JD Carr, YR Nersesova, D Markham, KJ Strissel, AA Watkins, M Zhu, MY Donath, EC Drobny, EC Abramson, G Baumann, K Duvel, JL Yecies, S Menon, P Raman, AI Lipovsky, AL Souza, E Triantafellow, Q Ma, R Gorski, S Cleaver, MJ Ebstein W, JA Ehses, A Perren, E Eppler, P Ribaux, JA Pospisilik, R Maor-Cahn, X Gueripel, H Ellingsgaard, MK Schneider, G Biollaz, SC Eisenbarth, A Williams, OR Colegio, H Meng, T Strowig, A Rongvaux, J Henao-Mejia, CA Thaiss, S Joly, DG Gonzalez, E Erbay, VR Babaev, L Makowski, KN Charles, ME Snitow, S Fazio, MF Linton, B Everts, E Amiel, AM Smith, WY Lam, V Redmann, TC Freitas, R Faggioni, G Fantuzzi, C Gabay, A Moser, CA Dinarello, KR Feingold, C Grunfeld, R Fan, A Toubal, S Goni, K Drareni, Z Huang, F Alzaid, R Ballaire, P Ancel, N Liang, A Damdimopoulos, M Soued, I Staprans, LA Gavin, ME Donahue, BJ Huang, AH Moser, R Gulli, R Feinstein, H Kanety, MZ Papa, B Lunenfeld, A Karasik, M Feuerer, L Herrero, D Cipolletta, A Naaz, J Wong, A Nayer, AB Goldfine, C Benoist, S Shoelson, B Feve, JP Bastard, K Fischer, HH Ruiz, K Jhun, B Finan, DJ Oberlin, V van der Heide, AV Kalinovich, N Petrovic, Y Wolf, C Clemmensen, MJ Fox, JF Kuzma, WT Washam, MD Fullerton, GR Steinberg, JD Schertzer, R Fucho, CZ Gorgun, G Tuncman, Y Furusawa, Y Obata, S Fukuda, TA Endo, G Nakato, D Takahashi, Y Nakanishi, C Uetake, K Kato, T Kato, JJ Fuster, MA Zuriaga, D Thi-Minh Ngo, MG Farb, T Aprahamian, TP Yamaguchi, N Gokce, K Walsh, S Galic, S Sikkema, K Marcinko, CR Walkley, D Izon, J Honeyman, ZP Chen, BJ van Denderen, Z Gao, D Hwang, F Bataille, M Lefevre, D York, MJ Quon, J Ye, MR Ghazarian, S X, MK Nojr, H Luck, K Zeng, H Lei, S Tsai, SA Schroer, YJ Park, MHY Chng, L Shen, JA D'Angelo, P Horton, WC Chapman, D Brockmeier, M Woo, EG Engleman, O Adeyi, N Hirano, T Jin, AJ Gehring, S Winer, DA Winer, B Ghesquiere, BW Wong, A Kuchnio, P Carmeliet, B Gonzalez-Teran, N Matesanz, I Nikolic, MA Verdugo, V Sreeramkumar, L Hernandez-Cosido, A Mora, G Crainiciuc, ML Saiz, E Bernardo, TE Graham, Q Yang, M Bluher, A Hammarstedt, TP Ciaraldi, RR Henry, CJ Wason, A Oberbach, PA Jansson, U Smith, EA Green, RA Flavell, ME Griffin, MJ Marcucci, GW Cline, K Bell, N Barucci, D Lee, LJ Goodyear, EW Kraegen, GI Shulman, FX Hausberger, B Hellman, L Helson, E Carswell, E Elinav, EC Hett, LH Slater, KG Mark, T Kawate, BG Monks, A Stutz, E Latz, DT Hung, AA Hill, W Reid Bolus, AH Hasty, J Hirosumi, L Chang, KT Uysal, K Maeda, EG Hong, HJ Ko, YR Cho, Z Ma, TY Yu, RH Friedline, E Kurt-Jones, R Finberg, MA Fischer, P Arner, JF Caro, RL Atkinson, BM Spiegelman, DL Murray, LN Choy, P Peraldi, A Budavari, R Ellis, NS Shargill, J Huang, N Liao, QP Huang, ZF Xie, JY Huang, MT Chiang, SF Yet, LY Chau, A Ichimura, A Hirasawa, O Poulain-Godefroy, A Bonnefond, T Hara, L Yengo, I Kimura, A Leloire, N Liu, K Iida, WKE Ip, N Hoshi, DS Shouval, S Snapper, R Medzhitov, CO Jacob, S Aiso, SA Michie, HO McDevitt, H Acha-Orbea, AB Jenkins, LH Storlien, DJ Chisholm, AK Jha, A Sergushichev, V Lampropoulou, Y Ivanova, E Loginicheva, K Chmielewski, KM Stewart, J Ashall, Y Ji, S Sun, A Xu, L Yang, KS Lam, B Gao, S Kersten, L Qi, AB Johnson, M Argyraki, JC Thow, BG Cooper, G Fulcher, R Taylor, FR Jornayvaz, AL Birkenfeld, MJ Jurczak, S Kanda, BA Guigni, DC Jiang, D Zhang, HY Lee, VT Samuel, D Jullien, JF Tanti, SJ Heydrick, N Gautier, T Gremeaux, E Van Obberghen, Y Le Marchand-Brustel, H Kaneto, Y Nakatani, T Miyatsuka, D Kawamori, TA Matsuoka, M Matsuhisa, Y Kajimoto, H Ichijo, Y Yamasaki, M Hori, R Hemi, PA Kern, M Saghizadeh, JM Ong, RJ Bosch, R Deem, RB Simsolo, T Higashimori, SY Park, H Choi, J Dong, YJ Kim, HL Noh, G Cline, YB Kim, JK Kim, JJ Fillmore, MJ Sunshine, B Albrecht, DW Kim, ZX Liu, TJ Soos, WR O'Brien, A Kleinridders, D Schenten, AC Konner, BF Belgardt, J Mauer, T Okamura, FT Wunderlich, JC Bruning, D Kolodin, N van Panhuys, AM Magnuson, CM Miller, A Wagers, RN Germain, D Mathis, E Kopp, S Ghosh, A Kosteli, E Sugaru, G Haemmerle, JF Martin, J Lei, R Zechner, V Kothari, JA Galdo, ST Mathews, M Koulmanda, M Bhasin, Z Awdeh, A Qipo, Z Fan, D Hanidziar, P Putheti, H Shi, E Csizuadia, TA Libermann, M Kratz, BR Coats, KB Hisert, D Hagman, V Mutskov, E Peris, KQ Schoenfelt, JN Kuzma, I Larson, PS Billing, H Kwon, S Laurent, Y Tang, H Zong, P Vemulapalli, JE Pessin, GI Lancaster, MA Febbraio, CH Lang, C Dobrescu, JY Lee, HS Youn, WH Lee, L Zhao, N Sizemore, DH Hwang, MW Lee, JI Odegaard, L Mukundan, Y Qiu, AB Molofsky, JC Nussbaum, K Yun, RM Locksley, AP Petkova, JG Granneman, M Li, DH Kim, PL Tsenovoy, SJ Peterson, R Rezzani, LF Rodella, WS Aronow, S Ikehara, NG Abraham, P Li, M Lu, G Bandyopadhyay, D Oh, T Imamura, AM Johnson, D Sears, Z Shen, B Cui, Z Li, MJ Soloski, AM Diehl, H Liang, B Yin, H Zhang, S Zhang, Q Zeng, J Wang, X Jiang, L Yuan, CY Wang, PR Ling, BR Bistrian, B Mendez, NW Istfan, AE Locke, B Kahali, SI Berndt, AE Justice, TH Pers, FR Day, C Powell, S Vedantam, ML Buchkovich, J Yang, S Loffreda, SQ Yang, HZ Lin, CL Karp, ML Brengman, DJ Wang, AS Klein, GB Bulkley, C Bao, PW Noble, JW Lowenthal, DW Ballard, E Bohnlein, WC Greene, JL Bodzin, AR Saltiel, SM Deyoung, L Lynch, K Maedler, P Sergeev, F Ris, J Oberholzer, HI Joller-Jemelka, GA Spinas, N Kaiser, PA Halban, JR Mahoney, BA Beutler, N Le Trang, W Vine, Y Ikeda, M Kawakami, PD Miles, OM Romeo, K Higo, A Cohen, K Rafaat, JM Olefsky, HE Liang, SJ Van Dyken, LE Cheng, A Mohapatra, M Monetti, MC Levin, MJ Watt, MP Sajan, S Marmor, BK Hubbard, RD Stevens, JR Bain, CB Newgard, RV Farese, DL Morris, JL Delproposto, KE Oatmen, LM Geletka, G Martinez-Santibanez, R Mounier, M Theret, L Arnold, S Cuvellier, L Bultot, O Goransson, N Sanz, A Ferry, K Sakamoto, M Foretz, J An, MJ Muehlbauer, LF Lien, AM Haqq, SH Shah, M Arlotto, CA Slentz, X Cui, J Mwangi, T David, F Brombacher, S Nishimura, I Manabe, M Nagasaki, K Eto, H Yamashita, M Ohsugi, M Otsu, K Hara, K Ueki, S Sugiura, S Takaki, J Sugita, K Yoshimura, I Komuro, LA O'Neill, DG Hardie, DY Oh, S Talukdar, EJ Bae, H Morinaga, W Fan, WJ Lu, A Oliff, D Defeo-Jones, M Boyer, D Martinez, D Kiefer, G Vuocolo, A Wolfe, SH Socher, EA Oral, SM Reilly, AV Gomez, R Meral, L Butz, N Ajluni, TL Chenevert, E Korytnaya, AH Neidert, R Hench, L Osborn, S Kunkel, GJ Nabel, N Ouchi, A Higuchi, K Ohashi, Y Oshima, R Shibata, Y Akasaki, A Shimono, U Ozcan, Q Cao, E Yilmaz, AH Lee, NN Iwakoshi, E Ozdelen, C Gorgun, LH Glimcher, J Palmblad, D Hallberg, L Engstedt, N Pamir, NC Liu, A Irwin, L Becker, Y Peng, GE Ronsein, KE Bornfeldt, JS Duffield, JW Heinecke, SH Park, Z Liu, Y Sui, RN Helsley, B Zhu, DK Powell, C Zhou, P Pekala, MD Lane, MC Petersen, AK Madiraju, BM Gassaway, M Marcel, AR Nasiri, G Butrico, A Abulizi, XM Zhang, P Plomgaard, K Bouzakri, R Krogh-Madsen, B Mittendorfer, JR Zierath, BK Pedersen, CP Fischer, T Ibfelt, G van Hall, X Tian, RD Palmiter, D Rabinowitz, KL Zierler, PJ Randle, PB Garland, CN Hales, EA Newsholme, ME Rausch, S Weisberg, P Vardhana, DV Tortoriello, RM Raymond, JM Harkema, TE Emerson, SH Chiang, SJ Decker, M Uhm, MJ Larsen, JR Rubin, J Mowers, NM White, I Hochberg, C Reinhard, B Shamoon, V Shyamala, LT Williams, RR Ricardo-Gonzalez, A Red Eagle, H Jouihan, CR Morel, JE Heredia, D Wu, G Sabio, M Das, Z Zhang, JY Jun, T Barrett, RJ Davis, WT Garvey, AJ Scheen, N Esser, N Paquot, H Sell, C Habich, J Eckel, CN Serhan, C Serra, M Federici, A Buongiorno, MI Senni, S Morelli, E Segratella, M Pascuccio, C Tiveron, E Mattei, L Tatangelo, B Shan, X Wang, Y Wu, C Xu, Z Xia, J Dai, M Shao, F Zhao, S He, D Shungin, TW Winkler, DC Croteau-Chonka, T Ferreira, R Magi, RJ Strawbridge, N Silswal, AK Singh, B Aruna, S Mukhopadhyay, NZ Ehtesham, PM Smith, MR Howitt, N Panikov, M Michaud, CA Gallini, YM Bohlooly, JN Glickman, WS Garrett, RG Snodgrass, S Huang, IW Choi, JC Rutledge, D Artis, SC Sookoian, C Gonzalez, CJ Pirola, O Spadaro, CD Camell, L Bosurgi, KY Nguyen, YH Youm, CV Rothlin, VD Dixit, M Spite, J Claria, JJ Spitzer, K Meszaros, JL Barlow, JP Mizgerd, JM Stephens, CM Steppan, ST Bailey, S Bhat, EJ Brown, RR Banerjee, CM Wright, HR Patel, RS Ahima, MA Lazar, T Koenen, B van Tits, JA van Diepen, SA van den Berg, PC Rensen, PJ Voshol, MH Zaki, FL van de Veerdonk, D Perera, GA Neale, GJ Hooiveld, I Vroegrijk, ME Shaul, G Bennett, AS Greenberg, MS Obin, J Szendroedi, T Yoshimura, E Phielix, C Koliaki, M Marcucci, T Jelenik, J Muller, C Herder, P Nowotny, NA Talbot, CP Wheeler-Jones, ME Cleasby, D Li, J Xu, J McNelis, Q Yan, Y Zhu, S Tanaka, S Inoue, F Isoda, M Waseda, M Ishihara, T Yamakawa, A Sugiyama, Y Takamura, K Okuda, GM Tannahill, AM Curtis, J Adamik, EM Palsson-McDermott, AF McGettrick, G Goel, C Frezza, NJ Bernard, B Kelly, NH Foley, DC Thurmond, E Oh, RA Miller, E Tsaousidou, L Paeger, M Pal, CM Wunderlich, H Bronneke, U Collienne, B Hampel, M Schmidt-Supprian, G Solinas, F Urano, A Bertolotti, P Chung, HP Harding, D Ron, SM Wiesbrock, MW Marino, T Van der Poll, JA Romijn, E Endert, JJ Borm, HR Buller, HP Sauerwein, B Vandanmagsar, A Ravussin, JE Galgani, K Stadler, RL Mynatt, E Ravussin, JR Vane, J Ventre, T Doebber, M Wu, K MacNaul, K Stevens, M Pasparakis, G Kollias, DE Moller, G Waeber, J Delplanque, C Bonny, V Mooser, M Steinmann, C Widmann, A Maillard, J Miklossy, C Dina, EH Hani, R Wang, DR Green, SP Weisberg, D McCann, M Desai, M Rosenbaum, RL Leibel, H Wen, D Gris, Y Lei, S Jha, L Zhang, MT Huang, WJ Brickey, JP Ting, I Wernstedt Asterholm, C Tao, TS Morley, QA Wang, F Delgado-Lopez, ZV Wang, PP Wadia, J Yantha, G Paltser, H Tsui, P Wu, MG Davidson, MN Alonso, Y Chan, D Truong, J Bahrami, R Dorfman, Y Wang, J Zielenski, F Mastronardi, S Boura-Halfon, N Cortese, Z Haimon, H Sar Shalom, Y Kuperman, V Kalchenko, A Brandis, E David, Y Segal-Hayoun, SC Woods, DP Begg, M Xie, Y Yu, R Kang, S Zhu, L Zeng, X Sun, M Yang, TR Billiar, H Wang, H Xu, GT Barnes, G Tan, D Yang, CJ Chou, J Sole, A Nichols, JS Ross, LA Tartaglia, H Yan, Y Gao, H Yang, JM Gimble, F Greenway, ES Calay, J Fan, A Arduini, RC Kunz, SP Gygi, A Yalcin, S Fu, N Mody, F Preitner, OD Peroni, JM Zabolotny, K Kotani, L Quadro, BB Kahn, MM Yore, I Syed, PM Moraes-Vieira, T Zhang, MA Herman, EA Homan, RT Patel, S Chen, C Yu, Y Chen, R Bergeron, SW Cushman, GJ Cooney, N Konstantopoulos, K Zhang, RJ Kaufman, X Zhang, G Zhang, H Bai, T Zhao, M Hou, M Xia, Q Wang, H Zhu, Y Xiao, Z Tang, J Ma, W Ling, Y Zhao, Z Jiang, E Delgado, H Li, H Zhou, W Hu, M Perez-Basterrechea, A Janostakova, Q Tan, R Zhou, A Tardivel, B Thorens, I Choi, J Tschopp Show less
Highly ordered interactions between immune and metabolic responses are evolutionarily conserved and paramount for tissue and organismal health. Disruption of these interactions underlies the emergence Show more
Highly ordered interactions between immune and metabolic responses are evolutionarily conserved and paramount for tissue and organismal health. Disruption of these interactions underlies the emergence of many pathologies, particularly chronic non-communicable diseases such as obesity and diabetes. Here, we examine decades of research identifying the complex immunometabolic signaling networks and the cellular and molecular events that occur in the setting of altered nutrient and energy exposures and offer a historical perspective. Furthermore, we describe recent advances such as the discovery that a broad complement of immune cells play a role in immunometabolism and the emerging evidence that nutrients and metabolites modulate inflammatory pathways. Lastly, we discuss how this work may eventually lead to tangible therapeutic advancements to promote health. Show less
no PDF DOI: 10.1016/j.immuni.2017.08.009
review
Ejidike IP, Ajibade PA. · 2016 · International Journal of Molecular Sciences · MDPI · added 2026-05-01
The current work reports the synthesis, spectroscopic studies, antiradical and antiproliferative properties of four ruthenium(III) complexes of heterocyclic tridentate Schiff base bearing a simple 2', Show more
The current work reports the synthesis, spectroscopic studies, antiradical and antiproliferative properties of four ruthenium(III) complexes of heterocyclic tridentate Schiff base bearing a simple 2',4'-dihydroxyacetophenone functionality and ethylenediamine as the bridging ligand with RCHO moiety. The reaction of the tridentate ligands with RuCl₃·3H₂O lead to the formation of neutral complexes of the type [Ru(L)Cl₂(H₂O)] (where L = tridentate NNO ligands). The compounds were characterized by elemental analysis, UV-vis, conductivity measurements, FTIR spectroscopy and confirmed the proposed octahedral geometry around the Ru ion. The Ru(III) compounds showed antiradical potentials against 2,2-Diphenyl-1-Picrylhydrazyl (DPPH) and 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radicals, with DPPH scavenging capability in the order: [(PAEBOD)RuCl₂] > [(BZEBOD)RuCl₂] > [(MOABOD)RuCl₂] > [Vit. C] > [rutin] > [(METBOD)RuCl₂], and ABTS radical in the order: [(PAEBOD)RuCl₂] < [(MOABOD)RuCl₂] < [(BZEBOD)RuCl₂] < [(METBOD)RuCl₂]. Furthermore, in vitro anti-proliferative activity was investigated against three human cancer cell lines: renal cancer cell (TK-10), melanoma cancer cell (UACC-62) and breast cancer cell (MCF-7) by SRB assay. Show less
📄 PDF DOI: 10.3390/ijms17010060
Biometal
Ejidike IP, Ajibade PA. · 2016 · Bioinorganic Chemistry and Applications · added 2026-05-01
Mononuclear Ru(III) complexes of the type [Ru(LL)Cl2(H2O)] (LL = monobasic tridentate Schiff base anion: (1Z)-N'-(2-{(E)-[1-(2,4-dihydroxyphenyl)ethylidene]amino}ethyl)-N-phenylethanimidamide [DAE], 4 Show more
Mononuclear Ru(III) complexes of the type [Ru(LL)Cl2(H2O)] (LL = monobasic tridentate Schiff base anion: (1Z)-N'-(2-{(E)-[1-(2,4-dihydroxyphenyl)ethylidene]amino}ethyl)-N-phenylethanimidamide [DAE], 4-[(1E)-N-{2-[(Z)-(4-hydroxy-3-methoxybenzylidene)amino]ethyl}ethanimidoyl]benzene-1,3-diol [HME], 4-[(1E)-N-{2-[(Z)-(3,4-dimethoxybenzylidene)amino]ethyl}ethanimidoyl]benzene-1,3-diol [MBE], and N-(2-{(E)-[1-(2,4-dihydroxyphenyl)ethylidene]amino}ethyl)benzenecarboximidoyl chloride [DEE]) were synthesized and characterized using the microanalytical, conductivity measurements, electronic spectra, and FTIR spectroscopy. IR spectral studies confirmed that the ligands act as tridentate chelate coordinating the metal ion through the azomethine nitrogen and phenolic oxygen atom. An octahedral geometry has been proposed for all Ru(III)-Schiff base complexes. In vitro anticancer studies of the synthesized complexes against renal cancer cells (TK-10), melanoma cancer cells (UACC-62), and breast cancer cells (MCF-7) was investigated using the Sulforhodamine B assay. [Ru(DAE)Cl2(H2O)] showed the highest activity with IC50 valves of 3.57 ± 1.09, 6.44 ± 0.38, and 9.06 ± 1.18 μM against MCF-7, UACC-62, and TK-10, respectively, order of activity being TK-10 < UACC-62 < MCF-7. The antioxidant activity by DPPH and ABTS inhibition assay was also examined. Scavenging ability of the complexes on DPPH radical can be ranked in the following order: [Ru(DEE)Cl2(H2O)] > [Ru(HME)Cl2(H2O)] > [Ru(DAE)Cl2(H2O)] > [Ru(MBE)Cl2(H2O)]. Show less
📄 PDF DOI: 10.1155/2016/9672451
Biometal
Wirth S, Wallek AU, Zernickel A +6 more · 2010 · Journal of Inorganic Biochemistry · Elsevier · added 2026-05-01
The synthesis, structural characterization and biological activity of eight ortho-quinone(N-aryl)-oximine rhenium(I) complexes are described. The reaction of the halogenido complexes (CO)(5)ReX (X = C Show more
The synthesis, structural characterization and biological activity of eight ortho-quinone(N-aryl)-oximine rhenium(I) complexes are described. The reaction of the halogenido complexes (CO)(5)ReX (X = Cl (4), Br (5)) with 2-nitroso-N-arylanilines {(C(6)H(3)ClNO)NH(C(6)H(4)R)} (R = p-Cl, p-Me, o-Cl, H) (3a-d) in tetrahydrofurane (THF) yields the complexes fac-(CO)(3)XRe{(C(6)H(3)ClNO)NH(C(6)H(4)R)} (6a-d, 7a-d) with the tautomerized ligand acting as a N,N'-chelate. The substitution of two carbonyl ligands leads to the formation of a nearly planar 5-membered metallacycle. During coordination the amino-proton is shifted to the oxygen of the nitroso group which can be observed in solution for 6 and 7 by (1)H NMR spectroscopy and in solid state by crystal structure analysis. After purification, all compounds have been fully characterized by their (1)H and (13)C NMR, IR, UV/visible (UV/Vis) and mass spectra. The X-ray structure analyses revealed a distorted octahedral coordination of the CO, X and N,N'-chelating ligands for all Re(I) complexes. Biological activity of four oximine rhenium(I) complexes was assessed in vitro in two highly aggressive cancer cell lines: human metastatic melanoma A375 and human chronic myelogenous leukemia K562. Chlorido complexes (6a and 6c) were more efficient than bromido compounds (7d and 7b) in inducing apoptotic cell death of both types of cancer cells. Melanoma cells were more susceptible to tested rhenium(I) complexes than leukemia cells. None of the ligands (3a-d) showed any significant anticancer activity. Show less
📄 PDF DOI: 10.1016/j.jinorgbio.2010.03.014
Biometal apoptosis